| 1 min read
Register for free to listen to this article
Listen with Speechify
0:00
1:00
MOUNTAIN VIEW, Calif.—On the same day that it announced the signing of a major research col­laboration with GSK (see story), ChemoCentryx announced it completed $17.7 million in Series C financing. When added to the $63.5 million in upfront fund­ing it will receive from GSK and other financing vehicles, ChemoCentryx has achieved about $90 million in new mon­ies in 2006.
 
"Historically, we have suc­cessfully pursued a mix of venture capital financing and non-dilutive funding," said Dr. Thomas J. Schall, company president and CEO, in a pre­pared statement. "The combi­nation of our Series C financ­ing and the upfront payments received as part of our strategic alliance with GSK reinforces this long-term strategy. We are now extremely well-positioned to avail ourselves of market opportunities of our choosing, as we continue to build value in ChemoCentryx and our pipe­line of chemokine-based medicines."
 
The Series C investors include Jennison Associates, HBM BioVentures, Orbimed Advisors, Techne Corporation, Alta Partners and GIMV.

About the Author

Related Topics

Published In

Loading Next Article...
Loading Next Article...
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

Gold circles with attached purple corkscrew shapes represent gold nanoparticles against a black background.

Driving gene therapy with nonviral vectors 

Learn why nonviral vectors are on the rise in gene therapy development.
A 3D digital illustration of a viral spike protein on a cell surface, surrounded by colorful, floating antibodies in the background

Milestone: Leapfrogging to quantitative, high throughput protein detection and analysis

Researchers continuously push the boundaries of what’s possible with protein analysis tools.
Blue cancer cells attached to a cellular surface against a bright blue background in a 3D rendering of a cancer infection.

Advancing immuno-oncology research with cellular assays

Explore critical insights into immunogenicity and immunotoxicity assays for cancer therapies.
Drug Discovery News November 2024 Issue
Latest IssueVolume 20 • Issue 6 • November 2024

November 2024

November 2024 Issue

Explore this issue